For the Treatment of Type 2 Diabetes, the Vast Majority of Surveyed Physicians in China and South Korea Indicate That There is a Need for GLP-1 Analogues Other Than Byetta

Interviewed South Korean Payers Expect Victoza and Bydureon To Be Reimbursed Under National Health Insurance, According to a New Report from Decision Resources BURLINGTON, Mass. -- Decision Resources, one of [...]